Oct 21, 2019 / 01:30PM GMT
Operator
Good day, and welcome to the Sartorius and Sartorius Stedim Biotech conference call. Today's conference is being recorded.
At this time, I would like to turn the conference over to Dr. Joachim Kreuzburg, CEO. Please go ahead, sir.
Joachim Kreuzburg - Sartorius Aktiengesellschaft - Chairman of Executive Board & CEO
Thank you very much. Welcome, everybody, to our today's conference call on both the proposed acquisition of select assets from Danaher life science as well as on our 9-month results for 2019. We would like to start off by walking you through some details regarding the proposed acquisition, and then we would like to focus on the 9-month results, first for the Sartorius Group; and then for Sartorius Stedim Biotech; and after that, we will have time for questions and answers.
So let's start by focusing on the proposed acquisition of select assets from Danaher Life Science. As you can see on this chart, this acquisition includes the portfolio of 3 businesses, with all having a strong complementary fit to the businesses of Sartorius
Nine Months 2019 Sartorius AG Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot